Neoadjuvant treatment with tyrosine kinase inhibitors in patients with resectable non-small cell lung cancer
Entity
UAM. Departamento de MedicinaPublisher
AME Publishing Company.Date
2019-09-23Citation
10.21037/jtd.2019.09.68
Journal of Thoracic Disease 11.10 (2019): 4092-4095
ISSN
2072-1439 (print); 2077-6624 (online)DOI
10.21037/jtd.2019.09.68Editor's Version
http://dx.doi.org/10.21037/jtd.2019.09.68Subjects
Tumour; Cancer; Chemoradiotherapy; Risk of death; MedicinaRights
© 2019 Journal of Thoracic DiseaseEsta obra está bajo una licencia de Creative Commons Reconocimiento-NoComercial-SinObraDerivada 4.0 Internacional.
Files in this item
Google Scholar:Franco, Fernando
-
Provencio Pulla, Mariano
This item appears in the following Collection(s)
Related items
Showing items related by title, author, creator and subject.
-
KRAS p.G12C mutation occurs in 1% of EGFR-mutated advanced non-small-cell lung cancer patients progressing on a first-line treatment with a tyrosine kinase inhibitor
Serna-Blasco, R.; Sánchez-Herrero, E.; Sanz-Moreno, S.; Rodriguez-Festa, A.; García-Veros, E.; Casarrubios, M.; Sierra-Rodero, B.; Laza-Briviesca, R.; Cruz-Bermúdez, A.; Mielgo-Rubio, X.; Sánchez-Hernández, A.; Uribelarrea, E. A.; Calvo de Juan, Virginia; Romero, A.; Provencio Pulla, Mariano
2021-10-01 -
Concordance between circulating tumor cells and clinical status during follow-up in anaplastic lymphoma kinase (ALK) non-small-cell lung cancer patients
Provencio Pulla, Mariano; Pérez-Callejo, David; Torrente, María; Martín, Paloma; Calvo de Juan, Virginia; Gutiérrez, Lourdes; Franco, Fernando; Coronado, María José; Cruz-Bermúdez, Juan Luis; Martín Ruiz-Valdepeñas, Asunción; Cruz-Bermúdez, Alberto; Sánchez-Beato, Margarita; Romero, Atocha; García-Grande, Aránzazu
2017-07-31